Full-Time
Biotechnology tools for genomic research
$133.7k - $180.9k/yr
Senior
Pleasanton, CA, USA
The territory includes the Americas Region, and candidates from different regions within the US are considered.
Get referrals →
You have ways to get a 10x Genomics referral from your network.
Applications through a referral are 3x more likely to get an interview!
Upload your resume to see how it matches 3 keywords from the job description.
PDF, DOC, DOCX, up to 4 MB
10x Genomics creates tools for genomic research, focusing on single-cell analysis, spatial gene expression, and immune profiling. Their products, which include laboratory equipment and software for data analysis, help researchers gain detailed insights into genetic information. Unlike competitors, 10x Genomics specializes in high-resolution genomic data that supports personalized medicine. The company's goal is to enable scientists to better understand complex biological systems and advance healthcare.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Pleasanton, California
Founded
2012
Help us improve and share your feedback! Did you find this helpful?
Comprehensive health benefits
Generous time off
Parental leave
ROCKVILLE, Md., May 5, 2025 /PRNewswire/ -- Psomagen Inc., a multiomics service laboratory serving academic, pharma, biotech, and clinical customers, will join the Billion Cells Project led by the Chan Zuckerberg Initiative (CZI). The Billion Cells Project aims to develop a landmark single-cell dataset of one billion cells that will be used to train new AI models to advance researchers' understanding of cellular behavior and gene function. Psomagen has begun providing services to participating researchers in April. The project includes collaborations with several other technology partners, including Ultima Genomics, 10x Genomics and Scale Biosciences. Su Hong, CEO of Psomagen, says, "This project represents a transformative step in biomedical research, enabling the identification of novel therapeutic targets and guiding drug development with unparalleled precision. By leveraging AI-powered analysis on vast single-cell datasets, we aim to accelerate the discovery of new ways to restore diseased cells to health
Cardillo joins from 10x Genomics, where she served as Vice President of Corporate Communications.
10x Genomics' ATAC-Seq patents found valid and infringedPLEASANTON, Calif., March 3, 2025 /PRNewswire/ -- 10x Genomics (Nasdaq: TXG), a leader in single-cell and spatial biology, today provided an update on its patent litigation with Parse Biosciences. Through a consent agreement entered on February 25, 2025, in the United States District Court for the District of Delaware, Parse agreed - a week before trial was to start - to a worldwide permanent injunction that prevents it from making, using, selling or offering for sale its planned ATAC and ATAC-Multiome Single Cell products. As part of this consent agreement, Parse admitted that 10x's ATAC-seq patents are valid, enforceable and infringed by Parse's use of ATAC-seq methods and compositions."This development further validates the strength of our broad patent portfolio, which helps protect and preserve the world-class innovation engine at 10x," said Eric S. Whitaker, Chief Legal Officer of 10x Genomics. "We are pleased with this resolution on ATAC as we continue to defend the asserted Brenner patents on appeal."The company's litigation against Parse's gene expression products remains ongoing, with additional asserted patents under appeal. Following entry of the injunction, the trial scheduled for March 2025 concerning 10x's remaining patent infringement claims against Parse has been stayed pending those appeals.10x Genomics is committed to defending its intellectual property and investing in groundbreaking technologies that empower researchers worldwide.About 10x Genomics10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health
New single cell and spatial innovations extend 10x Genomics' technology and performanceleadership across all three platformsPLEASANTON, Calif., Feb. 23, 2025 /PRNewswire/ -- At the Advances in Genome Biology and Technology (AGBT) General Meeting, 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced a series of new product innovations to solidify its position as the best partner for high-performance single cell research at scale. In addition, the company unveiled a robust new product roadmap for its Visium and Xenium portfolios, extending its performance and technology leadership in the rapidly growing field of spatial biology."After a record year of innovation, we continue to push the boundaries of what's possible in single cell and spatial biology, taking on the hardest challenges so researchers can make the biggest impact," said Ben Hindson, Co-Founder and Chief Scientific Officer of 10x Genomics. "Our 2025 roadmap will once again raise the bar for the field and enable researchers to tackle bigger questions, analyze more samples and extract deeper insights from their data."10x Genomics will host a workshop at AGBT today, Sunday, February 23, at 1 p.m. ET to share the latest data and development directions across its three platforms
PLEASANTON, Calif., Feb. 18, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that members of its management team will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference on Tuesday, March 4, at 11:10 a.m. Eastern Time.Interested parties may access a live webcast of the fireside chat on the "Investors" section of the company's website at: https://investors.10xgenomics.com/. The webcast will be archived and available for replay for at least 45 days after the event.About 10x Genomics10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health. Our integrated solutions include instruments, consumables, and software for single cell and spatial biology, which help academic and translational researchers and biopharmaceutical companies understand biological systems at a resolution and scale that matches the complexity of biology